With new targets identified over the past few years, the development of precision medicine has expanded significantly. Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu, MD, from, Sidney Kimmel Cancer Center, Philadelphia, PA, explores the many new drugs that are currently being trialed. Dr Porcu discusses monoclocnal antibody IPH4102, which has shown promising results in Phase I trials as well as oligonucleotide miR-155 and immunotherapies including pembrolizumab.
